The future prospect of including CCR5 antagonists as a treatment option for management of HIV-1 infection in Sub-Saharan countries raises concern about the reliability of laboratory methods used to determine tropism of non-B subtypes and CRFs. This evidence concerns the gene CCR5 and HIV-1 infection.